内科

目的探讨基因检测联合彩色多普勒超声(CDUS)检查诊断甲状腺结节(TN)良恶性的临床应用价值。方法选取2018年10月至2020年10月本院收治的96例TN患者为研究对象，对患者进行BRAF基因检测和CDUS检查，以手术病理检查结果为金标准，比较BRAF基因检测、CDUS检查及二者联合检查鉴别TN良恶性的临床应用价值。结果96例TN患者中，手术病理检查结果确诊恶性结节患者39例，良性结节患者57例；BRAF基因检测、CDUS检查及两者联合检查诊断TN良恶性的灵敏度分别为74.36%、79.49%、94.87%，特异度分别为94.74%、70.18%、96.49%，准确率分别为86.46%、73.96%、95.83%，阳性预测值分别为90.63%、64.58%、94.87%，阴性预测值分别为84.38%、83.33%、96.49%，Kappa值分别为0.711、0.479、0.914。结论基因检测联合CDUS检查诊断甲状腺良恶性结节具有较高临床应用价值，可为临床治疗提供重要参考。

ObjectiveTo explore the clinical application value of gene test combined with color doppler ultrasound (CDUS) in the diagnosis of benign and malignant thyroid nodule (TN). MethodsA total of 96 TN patients admitted to our hospital from October 2018 to October 2020 were selected as the research objects. All the patients underwent BRAF gene test and CDUS examination. The results of surgical pathology were taken as the gold standard to compare the clinical application value of BRAF gene test, CDUS examination and their combination in differentiating benign and malignant TN. ResultsAmong 96 TN patients, 39 cases were diagnosed as malignant nodules and 57 cases were diagnosed as benign nodules by surgical pathological results. The sensitivity, specificity, accuracy, positive predictive values, negative predictive values and Kappa values of BRAF gene test, CDUS examination and their combination in the differential diagnosis of benign and malignant TN were (74.36%, 79.49%, 94.87%), (94.74%, 70.18%, 96.49%), (86.46%, 73.96%, 95.83%), (90.63%, 64.58%, 94.87%), (84.38%, 83.33%, 96.49%) and (0.711, 0.479, 0.914), respectively. ConclusionGene test combined with CDUS examination has high clinical value in differential diagnosis of benign and malignant TN, which can provide important reference for clinical treatment.